Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Lilly wows ADA with obesity results; Novo’s oral semaglutide data; first DMD gene therapy approved; the outlook for biopharma fundraising; and Korean pharma considers strategy in a changing world.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 30 June 2023, including: Eli Lilly and Company wows ADA with obesity results; Novo Nordisk A/S’s oral semaglutide data; first DMD gene therapy approved; the outlook for biopharma fundraising; and Korean pharma considers strategy in a changing world.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio" - Scrip, 26 Jun, 2023.)
(Also see "With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA" - Scrip, 25 Jun, 2023.)
(Also see "A Momentous Day For DMD: Sarepta’s Elevidys Is First Gene Therapy Approved" - Scrip, 22 Jun, 2023.)
(Also see "Biopharma Investors, Companies Learning To Adjust To Financial Market Realities" - Scrip, 27 Jun, 2023.)
(Also see "Survive Or Fall: Korean Strategy In Changing Big Pharma Environment" - Scrip, 27 Jun, 2023.)